Moreover, the Canakinumab Anti-inflammatory Thrombosis Outcome Study has demonstrated the beneficial effect of anti-inflammatory therapy targeting IL-1β on a recurrent cardiovascular event (22, 80). This evidence concerns the gene IL1B and deep vein thrombosis.